A systematic review of the literature was conducted to determine the estimates of and definitions for human papillomavirus (HPV) persistence in women following treatment of cervical intra-epithelial neoplasia (CIN). A total of 45 studies presented data on post-treatment HPV persistence among 6,106 women. Most studies assessed HPV persistence after loop excision (42%), followed by conization (7%), cryotherapy (11%), laser treatment (4%), interferon-alpha, therapeutic vaccination, and photodynamic therapy (2% each) and mixed treatment (38%). Baseline HPV testing was conducted before or at treatment for most studies (96%). Follow-up HPV testing ranged from 1.5 to 80 months after baseline. Median HPV persistence tended to decrease with increasing follow-up time, declining from 27% at 3 months after treatment to 21% at 6 months, 15% at 12 months, and 10% at 24 months. Post-treatment HPV persistence estimates varied widely and were influenced by patient age, HPV-type, detection method, treatment method, and minimum HPV post-treatment testing interval. Loop excision and conization appeared to outperform cryotherapy procedures in terms of their ability to clear HPV infection. This systematic review provides evidence for the substantial heterogeneity in post-treatment HPV DNA testing practices and persistence estimates.
A systematic review of the literature was conducted to determine the estimates of and definitions for human papillomavirus (HPV) persistence in women following treatment of cervical intra-epithelial neoplasia (CIN). A total of 45 studies presented data on post-treatment HPV persistence among 6,106 women. Most studies assessed HPV persistence after loop excision (42%), followed by conization (7%), cryotherapy (11%), laser treatment (4%), interferon-alpha, therapeutic vaccination, and photodynamic therapy (2% each) and mixed treatment (38%). Baseline HPV testing was conducted before or at treatment for most studies (96%). Follow-up HPV testing ranged from 1.5 to 80 months after baseline. Median HPV persistence tended to decrease with increasing follow-up time, declining from 27% at 3 months after treatment to 21% at 6 months, 15% at 12 months, and 10% at 24 months. Post-treatment HPV persistence estimates varied widely and were influenced by patient age, HPV-type, detection method, treatment method, and minimum HPV post-treatment testing interval. Loop excision and conization appeared to outperform cryotherapy procedures in terms of their ability to clear HPV infection. This systematic review provides evidence for the substantial heterogeneity in post-treatment HPV DNA testing practices and persistence estimates.
Persistent high-risk human papillomavirus (HR-HPV) infection is strongly and consistently associated with high-grade cervical intraepithelial neoplasia (CIN) grade 2/3 acquisition 1 and is considered essential for the progression of cervical precancer to invasive cervical cancer (ICC). 2 The American Society for
Colposcopy and Cervical Pathology (ASCCP) recommends that women with a histological diagnosis of CIN 2-3 receive ablative or excisional treatment to eliminate CIN and associated HPV infection. 3 However, a proportion of CIN 2-3 cases remain infected with HR-HPV even after treatment. 4, 5 Recurrent CIN may result from inadequate treatment of precancerous cervical lesions (i.e., treatment failure), incomplete removal of HPV infections resulting in HR-HPV infection persistence, re-infection with a new HR-HPV type, or persistence of another HPV type not associated with the primary cervical lesion. [6] [7] [8] In order to clinically monitor patients post-CIN treatment, follow-up strategies recommended by the ASCCP include HPV testing, cytology and colposcopy, either alone or in combination, at either 3-month or annual intervals. Given the higher sensitivity of HPV testing for CIN 2-3 detection relative to cytology or colposcopy, 9, 10 HPV testing is regularly utilized post-treatment in many clinical practices to aid in the early detection of recurrent CIN disease. 10 To date, there has been no summary of the literature that examines the estimates of and definitions for HPV persistence after CIN treatment. In 2014, we published a systematic review of HPV incidence after treatment for CIN. 11 In contrast to persistent HPV infections, which are infections that are present at or before treatment and remain present after treatment, incident HPV infections are defined as the detection of a new HPV genotype after treatment for CIN that was not present before or at the time of treatment. 11 To better understand the proportion of HPV-positive women who remain HPV-positive following treatment for cervical disease, we performed a systematic review to describe the persistence of HPV infection following treatment for CIN in the published literature. We also explored whether post-treatment HPV persistence differed by age, treatment method, HPV detection method, HPV categorization (type-specific vs. non-type specific), specific HPV genotype and other study characteristics. Findings from this systematic review may inform treatment and vaccine-related research, clinical practice and screening guidelines.
Methods

Literature search strategy
We searched PubMed/Medline, ISI Web of Science, CINAHL (excluding Medline), EMBASE and the Cochrane Library through May 08, 2013, without date or language restrictions to identify peer-reviewed articles reporting the persistence of HPV infection among women treated for CIN. Our keyword search was designed in consultation with a reference librarian at the UNC Health Sciences Library. The search contained a combination of terms for four major components: HPV (e.g., hpv, papillomavirus infections, human papillomavirus, etc.); cervical disease (e.g., uterine cervical neoplasms, cervical intraepithelial neoplasia, CIN, etc.); treatment (cryotherapy, large loop excision, LEEP, LLETZ, conization, etc.); and follow-up (e.g., follow up, clearance, post-treatment, treatment failure, treatment outcome) (See Appendix A for search details). Reference citations were imported into RefWorks (ProQuest, LLC, Ann Arbor, MI) to remove duplicate records. Abstracts were then sorted in Mendeley (Mendeley, London, UK).
Eligibility criteria
Abstracts were selected for full-text evaluation with respect to the following criteria: (i) patients had received treatment for CIN; (ii) post-treatment HPV testing was conducted; and (iii) the study sample was not composed entirely of patients with invasive cancer at baseline visit. Studies were included in the review after full-text evaluation if they met the following criteria: (i) publication was peer-reviewed, (ii) at least one post-treatment HPV measurement was reported, and (iii) at least one baseline HPV test was used to define HPV persistence. Studies using the following HPV diagnostic methods were included: first-generation hybrid capture (HC) or hybrid capture 2 (HC2; QIAGEN Corporation, Gaithersburg, MD), polymerase chain reaction (PCR) and PapilloCheck assay (Greiner BioOne, Frickenhausen, Germany).
Studies were excluded if they met the following criteria: HPV serology-only studies, and studies that included only anal, vulvar or labial specimens; oral HPV studies; studies on men; animal studies; simulation studies; and populations of exclusively HIV-positive women. Articles that did not state HIV serostatus were assumed to be HIV-negative and included. We also excluded studies using specimens obtained from self-sampling methods only; studies that changed the type of testing or specimen over time; and studies with insufficient post-treatment HPV data to calculate the percentage of women persistent for any specific follow-up time point.
Of the 4,349 records identified, 1,407 duplicate publications were found and removed using RefWorks (Fig. 1 ). An abstract review team screened the remaining 2,942 abstracts, and selected 269 articles for full-text assessment. The reference sections of all included articles were searched for other relevant articles. Of 142 relevant titles, 15 full-text articles were examined, and one was included (Fig. 1) , resulting in a final total of 45 publications included in the present review. Full text articles that were not published in English were translated and assessed for inclusion according to the same standards as English language articles. Of the included articles, none were published in a language other than English.
Data extraction
The following variables were extracted from publications that met the inclusion criteria: journal of publication, publication date, study dates, study design, geographic region and sample size. Participant characteristics included age and population description (e.g., clinical patients, population-based screening participants) and HIV positivity (if known). Treatment characteristics included methods used to detect cervical lesions (cytology vs. histology), grade of cervical lesions at time of treatment (e.g., CIN 1, CIN 2 and CIN 3), and treatment type (e.g., cryotherapy, conization and LEEP). HPV infection and testing characteristics included HPV specimen type (cervical cells vs. biopsy), HPV testing method (PCR vs. HC2), specific HPV types tested, and the timing of the first HPV test relative to treatment. Post-treatment characteristics included unit of analysis for incidence results (i.e., women, infections), follow-up HPV testing intervals, minimum follow-up time for defining HPV persistence, the number of persistent HPV infections reported, and persistent HPV types post-treatment. All data were independently extracted by two researchers to ensure accuracy. Inconsistencies in the extracted data were resolved by the two researchers until a consensus was reached.
HPV persistence definition and calculation
Women were considered to have "overall" HPV persistence if they tested positive for any type of HPV at two consecutive time points (i.e., baseline and first follow-up test used to define HPV persistence). If a woman tested positive for HR-HPV at both time points, she was considered to have persistent HR-HPV infection. Women were considered to have type-specific HPV persistence if they tested positive for the same HPV type at two consecutive time points (i.e., baseline and first follow-up test). The percentage of women with persistent HPV infection at a given time point following treatment was calculated as the number of women with a positive HPV test result at that time point divided by the number of all women who had presented as HPV-positive at the first time point (i.e., time of treatment) multiplied by 100.
Analysis
We examined persistence estimates by creating plots depicting the proportion of women with persistent HPV infection as the dependent variable and time since treatment as the independent variable. For each time point within each stratum, we calculated the median persistence estimate (i.e., the median percentage of women with persistent infection) across studies, and presented results in tabular format. For both graphical presentation and the presentation of median persistence estimates, we stratified plots by HPV type (HR versus overall); age group for the mean or median age in the study (<30, 30-34; 35 years of age); HPV detection method; HPV categorization (type-specific vs. non-type specific); treatment type; and minimum time between HPV testing time points for the determination of HPV persistence. Post-treatment HPV persistence estimates were graphically displayed according to study and sample characteristics and corresponding study follow-up time. HPV persistence estimates calculated for time points later than 25 months after treatment, exclusively defined for a given HPV type, or having fewer than five studies by treatment type, were not graphically displayed, but presented in tables.
Results
Eligible studies
A total of 45 studies 4,12-55 provided estimates on HPV persistence post-treatment in 6,106 women. Most studies were conducted in Europe (58%) and Asia/Australia (22%), with 18% from North/Central/South America, and 2% from multiple regions (Table 1 ). Overall, 84% of eligible studies were cohort studies, with data also available from three clinical trials and four case-control studies. Most studies reported HPV persistence post-treatment in women aged 30-39 (85%), and few studies reported a mean/median age <30 (4%), or 40 years of age (9%). Mean patient age ranged from 26.9 to 54.1 years (median 34.9; Table 2 ). Most studies (56%) used PCR to detect HPV infection, followed by HC-2 (22%), a combination of HC-2 and PCR (11%), first generation HC (9%) and PapilloCheck (2%). Cervical exfoliated cell specimens were the most commonly used specimen type for HPV detection (82%) as compared to biopsy specimens (13%).
High-risk HPV (HR-HPV) was the most frequently measured and reported HPV type (60%), followed by overall HPV (38%), with notably few studies reporting estimates stratified by HPV type: HPV 16 (7%), HPV 18 (7%), HPV 16/18 (2%) and HPV 16/18/33 (2%). In addition, few studies examined persistence of low-risk HPV (2%) or probable high-risk types (2%). The minimum duration of HPV persistence (follow-up time) was <6 months (47%), or 6 months to <1 year (36%) in most studies, with only 18% lasting one year or longer. Follow-up time for measuring HPV persistence ranged from 1.5 to 80 months after CIN treatment ( Table 2 ).
The vast majority of studies (96%) measured baseline HPV (which defined the initial HPV positivity for HPV persistence measurement) before or at CIN treatment/diagnosis. Only two studies 23, 51 (4%) investigated HPV persistence among newly acquired infection after treatment (Table 1) .
Although 53% of included studies reported estimates that were type-specific, these estimates were not usually stratified by HPV type. Instead, persistence estimates were most often reported with HPV types combined into overall or HR-HPV groupings. Most studies (96%) used women as the unit of analysis for HPV persistence, and few (7%) used HPV infections as the unit of analysis (one study reported both: Jones et al. 39 ). Approximately half (51%) of the studies provided estimates of HPV persistence in populations treated for CIN 2/3, followed by CIN 1-3 (33%), CIN 2 (2%) or CIN 3 (7%), CIN 1/2 (4%) and CIN 1 (2%).
Most studies used histology as the final classification method to diagnose cervical neoplasia (82%), while seven studies (16%) used a combined histology/cytology classification and one did not state the diagnostic classification method. 28 There was considerable heterogeneity in treatment types utilized among the studies: 42% used loop excision; 11% cryotherapy; 7% conization; 4% laser treatment; one study each used alphainterferon, photodynamic therapy, or therapeutic vaccination (2% each); while 38% used multiple treatment regimens without reporting treatment-specific results.
Post-treatment HPV persistence
Overall, HPV infection tended to gradually clear after CIN treatment for the different treatment modalities. As expected, median estimates of HPV persistence tended to decrease with increasing follow-up time: Median HPV persistence was 27% at 3 months, 21% at 6 months, 15% at 12 months and 10% at 24 months post-treatment (Appendix B Fig. 1 ). One study did not follow this pattern, and reported 100% HPV persistence at 6 and 12 months (n 5 20, overall HPV, interferonalpha treatment). 55 Post-treatment HPV persistence stratified by high risk and overall HPV type groupings HR-HPV persistence estimates were generally higher than for overall HPV (Table 3 ; Appendix B Fig. B1 ). In studies reporting results for HR-HPV, a median of 28% of women remained HR-HPV-positive (persistent) 3 months after treatment (Appendix B Fig. B1 ). The median proportion of women with persistent HR-HPV infection appeared to increase with increasing follow-up time: 22% at 6 months, 31% at 12 months, 32% at 24 months, but this observation was limited by relatively few studies reporting estimates for later posttreatment time points. In studies reporting overall HPV persistence (i.e., not restricted to HR-HPV types), median HPV persistence after treatment was 13% at 12 months and 4% at 24 months (Appendix B Fig. B1 ). There were limited data on type-specific HPV 16, HPV 18, HPV 33 persistence results, with no data available for other specific HPV types (Table 1) .
Post-treatment HPV persistence stratified by high risk and overall HPV groupings and age
The median proportion of women with persistent HR-HPV infection 6 months after treatment was 24% for studies with a mean or median age of 30-34 years and 28% for the 351 age group (Table 3 ; Appendix B Fig. B2 ; "age group" refers to the mean or median age of a study sample). Median HR-HPV persistence estimates for 24 months after treatment were 10% for the 30-34 years mean/median age group and 57% for the 351 age group. In contrast, for the overall-HPV definition of persistence, the median proportion of women with persistent HPV infection 6 months after treatment was 32% for the 30-34 years age group, and 10% for the 351 age group. Median overall-HPV persistence estimates for 24 months after treatment were 6% for the 30-34 years age group and 2% for the 351 age group. No individual studies examined post-treatment HPV infection stratified by age.
Post-treatment HPV persistence stratified by detection method
Post-treatment HPV persistence estimates were relatively higher in studies which utilized HC2 to detect HPV as compared to PCR (median estimates for HC2 and PCR: 42 vs. 25% at 3 months, 34 vs. 20% at 6 months, 31 vs. 13% at 12 months and 25 vs. 6% at 24 months), and fewer studies used HC2 (Table 3 ; Appendix B Fig. B3 ). A total of 5 studies used combined HC2 and PCR detection, with median HPV persistence estimates of 18% at 3 months and 26% at 6 months. Three studies used the HC detection method with a median HPV persistence estimate of 27% at 3 months.
Post-treatment HPV persistence stratified by persistence definition
Median type-specific HR-HPV estimates (i.e., persistence defined as positive test for the same HR-HPV type at two consecutive time points) were 18% at 3 months, 18% at 6 months and 57% at 24 months (Table 3 ; Appendix B Fig. B4 ). Nontype-specific HR-HPV results showed persistence estimates of 20-50% through 10 months of follow-up (median estimates: 31% at 3 months, 27% at 6 months, 31% at 12 months and 25% at 24 months). Among type-specific HR-HPV studies, women 35 years and older showed some of the highest persistence estimates among all groups (50-65%) (Appendix B Fig. B4 ). Typespecific overall-HPV persistence (i.e., persistence defined as positive test for the same HPV type at two consecutive time points for any combination of HPV types) ranged from 0-50% through 15 months follow-up (median estimates: 18% at 3 Median.
*The LEEP group in this study is from the same clinic and 4-year period as in the other study by Aerssens et al. Mini Review months, 20% at 6 months, 12% at 12 months and 4% at 24 months). Median non-type-specific overall-HPV estimates were 26% at 3 months, 57% at 6 months and 37% at 12 months.
Post-treatment HPV persistence stratified by treatment type
Conization and loop excision outperformed cryotherapy procedures in terms of their ability to clear HPV infection (Table 3 ; Appendix B Fig. B5 ).
Post-treatment HPV persistence stratified by time between treatment and first HPV test
In studies with an interval of <6 months between treatment and the first post-treatment HPV test (minimum follow-up time), median HPV persistence was 13% at 12 months, compared to 32% for studies with a 6 to 12 months minimum interval, and 13% for studies with a 121 months minimum interval (Table 3 ; Appendix B Fig. B6 ).
Discussion
This systematic review of over 6,000 women showed a decline in median post-treatment HPV persistence with increasing follow-up time. Notable heterogeneity in posttreatment HPV persistence estimates appeared to depend upon the treatment type, patient age, HPV type grouping, HPV detection method, and minimum interval between the two testing points to define HPV persistence. In light of the heterogeneity of the results and notable differences in study populations and methods utilized, we did not conduct a statistical meta-analysis of HPV persistence estimates posttreatment.
Baseline HPV testing to define HPV persistence was conducted before or at treatment for most included studies (96%) Appendix B Fig. B7 . Only two studies 23, 51 investigated the persistence of newly acquired HPV infections after treatment, thus limiting our ability to meaningfully characterize patterns of persistence for incident HPV infections acquired post-treatment. Thus, most of the persistence patterns that we report pertain to infections originating from before/at treatment and remaining after (i.e., patterns of posttreatment persistence of pre-treatment infections).
One of our previous systematic reviews 56 examined patterns of persistent HPV infection among women without treatment, and found a median duration (i.e., point at which 50% are persistent) of overall-HPV and of HR-HPV detection to be approximately 10 months, while in our present systematic review, estimates indicated HPV persistence to be relatively shorter in duration: 25% of women had a "persistent" HPV infection at 6 months after treatment, and 15% at 12 months post-treatment. The fact that HPV persistence values were relatively lower in our review of treated women is not surprising given that it is expected that most treatment modalities will result in the clearance/elimination of a notable proportion of HPV infections.
HPV persistence estimates differed according to the treatment method employed. Both loop excision and conization appeared to be associated with a relatively higher clearance (i.e., lower persistence) of HPV infections as compared to cryotherapy. Most of the included studies were observational studies without randomization, and thus, we cannot dismiss the potential influence of confounding factors, given that the treatment options and efficacy may vary notably based on differences in patient factors that can also influence treatment effectiveness.
Post-treatment HPV persistence estimates appeared to be somewhat higher for studies that utilized HC2 alone to detect HPV as compared to PCR alone. Type-specific persistence estimates were more restrictive in their definition of HPV persistence than non-type-specific estimates since they required that the patient test positive for the same HPV type at two or more consecutive time points in order to be counted as persistent. Since HC2 estimates measure HR-HPV persistence and thus were not type-specific per se, their numerators were more inclusive, thus providing a possible explanation for the larger persistence estimates. It is alternatively possible, however, that this observation of differences in persistence estimates by HPV detection method was attributable to differences in assay performance, treatment type, and other study-related factors.
There are several strengths of this review. First, we utilized a systematic approach which resulted in a large sample size of over 6,000 women and a comprehensive characterization of HPV persistence following CIN treatment reported in the present literature. Concerted efforts were made to include all published studies, including the translation of foreignlanguage publications (though none were found to be eligible for inclusion), and the review of references sections of all included articles. Extracted data were reviewed twice by independent readers to ensure data accuracy.
There are several limitations to our review which should be considered. Despite the large number of publications on HPV in the literature, 56 we were able to identify only 45 that reported sufficient information to calculate the percentage of women who remained persistently infected with HPV after CIN treatment. Due to the small number of studies with HIV-positive women, the results reported in this review are from studies enrolling entirely or almost entirely HIVnegative women, or women with unknown HIV status. Another limitation is that we limited our review to studies of clinician-collected sampling, and thus excluded studies using self-collected specimens. Of the 2,942 abstracts screened for this review, one study examined HPV persistence using selfsampling after CIN treatment. 57 Persistent HR-HPV infection via self-collection after laser CO2 conization treatment decreased over time: 51.2% at 3 months, 41.9% at 6 months and 22.5% at 12 months post-treatment. These estimates are near the range of our findings for HR-HPV persistence for clinician-collected sampling (Table 3) . Data were limited for women younger than 30 and older than 40 years of age. While we observed higher HPV persistence estimates from studies that reported HR-HPV persistence as compared with studies reporting any type of "overall" HPV persistence, HR-HPV estimates included in our review were usually not typespecific. Only four studies reported type-specific persistence for HPV 16 or 18, the two most common types implicated in invasive cervical cancer. 27, 42, 45, 54 One study 55 reported 100% HPV persistence, based on at least one follow-up time point among 20 women post interferon-alpha treatment. We believe these findings to be due to the investigational treatment utilized. Finally, we worked to ensure that there were no duplicate populations included in our review; however, two sets of studies included populations that may have overlapped, although this was unclear. 12, 13, 47, 52 Since the end date of our literature search in 2013, two larger studies of >100 women 58, 59 were published, with results similar to data presented in our present review. One study of 113 women in Turkey reported 21.2% HR-HPV persistence 12 months after cold-knife conization, 58 similar to the 12-month minimum HR-HPV persistence estimate reported in the present study (27.1%, Table 3 ). Among 358 women in China, HR-HPV persistence was 24.3% 3-months after LEEP, 59 consistent with the median HR-HPV post-LEEP persistence estimates in our review.
It should be noted that estimates of HPV persistence after treatment may represent either truly persistent infections (i.e., infections persisting from before treatment), recurrent HPV infections (i.e., reinfection after treatment), or newly acquired HPV infections (i.e., infections acquired after treatment). In light of our previous systematic review in women post-treatment, 11 a notable proportion of these "persistent" HPV infections may have been infections acquired after treatment. This is likely of particular concern for studies with long time intervals (i.e., 12 and 24 months) between HPV tests in which sexual activity and subsequent HPV exposure are likely to occur. However, HPV persistence estimates appeared to be higher in studies with a relatively shorter minimum interval between the first two testing time points to define persistence, suggesting that clearance of HPV infections is what was actually observed in most cases. Finally, even if CIN treatment successfully removes HPV from the cervical tissue, HPV still present in the vaginal mucosa may re-infect the cervix during follow-up. None of the included studies evaluated the vaginal/vulvar HPV prevalence after treatment.
Twenty-four studies in our review examined the association between post-treatment HPV infection and residual or recurrent CIN. 12, 14, [16] [17] [18] [19] 22, 25, 27, 29, 31, 34, 35, 37, 39, 40, [42] [43] [44] 46, 48, 49, 51, 52 Collectively these studies found that HPV testing after CIN treatment may help detect residual or recurrent disease, and that persistent HPV infection after treatment for CIN was an independent risk factor for recurrence. It is the general consensus of this literature that HPV testing should be incorporated into the follow-up of patients after treatment for CIN, though not as a replacement for either cytology or colposcopy follow-up procedures. This supports current ASCCP guidelines for post-treatment HPV testing as a screening option to identify women at an elevated risk of cervical disease recurrence following treatment. 3 Additional studies are needed, however to compare the clinical utility of testing for HPV infection post-treatment as compared with cytology or colposcopy.
Routine HPV testing after treatment of CIN 2-3 is recommended for early detection of disease recurrence or progression. 60 However, a recent Cochrane review was unable to find sufficient evidence from RCTs to inform the best posttreatment surveillance strategy.
61 While HR-HPV testing is more sensitive than follow-up cytology for detecting posttreatment high grade lesions, 9, 10 there is currently no consensus as to how to best apply post-treatment HPV testing (e.g., testing interval, follow-up time, number of post-treatment tests, assays used). 10 This systematic review offers evidence for substantial heterogeneity in post-treatment HPV DNA testing practices and persistence estimates. It was found that post-treatment screening results may be influenced by patient characteristics and choice of surveillance strategy (e.g., testing interval after treatment, detection method, overall or type-specific definition of persistence), demonstrating the need for research into optimization of HPV testing following treatment for CIN.
